Landmark Case in IP: The Diamond vs. Chakrabarty Case

The Diamond vs Chakrabarty case, decided by the U.S. Supreme Court in 1980, is a landmark ruling that revolutionised biotechnology patent law. The case established that genetically modified living organisms could be patented, if they are products of human ingenuity rather than naturally occurring entities.

Background and Facts

Ananda Mohan Chakrabarty, a genetic engineer working with General Electric, developed a bacterium, Pseudomonas putida (derived from the Pseudomonas genus), which is capable of metabolising hydrocarbons that constitute crude oil. This innovation was intended to help treat oil spills. When General Electric applied for a U.S. patent listing Chakrabarty as the inventor, the application was rejected based on two grounds: first, that micro- organisms are a "products of nature", and second, that living things are § 101 of Title 35 U.S.C not patentable subject matter under (https://unctad.org/ippcaselaw/sites/default/files/ippcaselaw/202012/Diamond%20v.%20Chakrabarty%2C%20447%20U.S.%20Supreme%20Court%20%20303%20%281980%29_0.pdf). Chakrabarty and General Electric appealed through the patent system, eventually reaching the U.S. Supreme Court.

Legal Issue

The central question was whether a human-made living organism constituted patentable subject matter under 35 U.S.C. § 101, which at that time covered "any new and useful process, machine, manufacture, or composition of matter". The U.S. Patent Office argued that living organisms, even if genetically engineered, were naturally excluded from patent protection.

Supreme Court Judgment

The Supreme Court, on 16 June 1980, ruled that “a live, human-made micro-organism is patentable subject matter under §101 and that the respondent's microorganism constitutes a "manufacture" or "composition of matter" within that statute (pp. 447 U.S. 308-318)”.  Furthermore, since said Pseudomonas putida did not occur naturally and was engineered for a specific, beneficial use, it fell within the intended scope of patents.

Conclusion

Diamond vs Chakrabarty stands as a foundational case for intellectual property law and innovation in biotechnology. Inspired by developments like Diamond v. Chakrabarty, India amended its patent laws to accommodate biotechnological inventions under the Patents Act, 1970, notably through amendments in 2002 aligning with TRIPS obligations (Article27.3(b)). The decision distinguished between discoveries and human-made inventions with distinctive characteristics and uses, broadening the scope of what could be patented under U.S. law.